Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.
Colleoni M, Bagnardi V, Rotmensz N, Viale G, Mastropasqua M, Veronesi P, Cardillo A, Torrisi R, Luini A, Goldhirsch A. Colleoni M, et al. Among authors: bagnardi v. Eur J Cancer. 2010 Aug;46(12):2216-24. doi: 10.1016/j.ejca.2010.04.008. Epub 2010 May 13. Eur J Cancer. 2010. PMID: 20471822
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.
Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A. Colleoni M, et al. Among authors: bagnardi v. Breast Cancer Res Treat. 2009 Jul;116(2):359-69. doi: 10.1007/s10549-008-0223-y. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941889 Clinical Trial.
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M. Balduzzi A, et al. Among authors: bagnardi v. Anticancer Drugs. 2009 Mar;20(3):197-203. doi: 10.1097/CAD.0b013e3283264719. Anticancer Drugs. 2009. PMID: 19182679
Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.
Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B. Guerrieri-Gonzaga A, et al. Among authors: bagnardi v. Oncologist. 2009 Mar;14(3):201-12. doi: 10.1634/theoncologist.2008-0203. Epub 2009 Mar 5. Oncologist. 2009. PMID: 19264824 Free article.
Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Botteri E, et al. Among authors: bagnardi v. Breast Cancer Res Treat. 2010 Jul;122(1):211-7. doi: 10.1007/s10549-009-0668-7. Epub 2009 Dec 6. Breast Cancer Res Treat. 2010. PMID: 19967556
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab.
Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, Dellapasqua S, Campagnoli E, Shaked Y, Goldhirsch A, Colleoni M, Bertolini F. Calleri A, et al. Among authors: bagnardi v. Clin Cancer Res. 2009 Dec 15;15(24):7652-7657. doi: 10.1158/1078-0432.CCR-09-1493. Clin Cancer Res. 2009. PMID: 19996223
307 results